Radstone Capital Group

Radstone Capital Group
Institutional Platform Across Private Credit and Healthcare Innovation
Radstone Capital Group is a private family held Australian-Malaysian investment holding group with strategic partnerships globally. The Group operates through a cohesive portfolio of specialist entities, each focused on high-conviction investment themes within private credit, medical technology, and healthcare services. The Group is structured to deliver disciplined deployment of capital, institutional governance, and long-term value creation across all its verticals.
RAB Capital Sdn Bhd serves as the Group's principal investing entity for deploying capital into the invoice factoring segment—a private credit strategy that provides liquidity to creditworthy businesses against trade receivables. RAB Capital manages end-to-end deployment through to execution and servicing of trade finance transactions with specialist factoring partners. With a proven track record in managing complex receivables portfolios, RAB Capital plays a central role in the Group's operations, ensuring disciplined risk management and transaction-level visibility.
Medicare Capital Group is the Group's healthcare-focused brand. Via Radstone Lifesciences (Australia), It holds equity in Opum Technologies, a U.S.-based medical technology firm specializing in AI-driven orthotic solutions that support post-operative recovery and musculoskeletal rehabilitation. In Malaysia, Medicare Capital is a key strategic partner to an Australian medical tourism platform, focused on high-quality, cross-border dental care and expanding into broader medical verticals.
Together, these entities reflect Radstone's integrated platform approach—where investment expertise, operational capability, and regulated structuring converge to deliver value across sectors and geographies. The Group maintains a clear focus on governance, scalability, and alignment of interests with its partners and counterparties.
Private Credit – High-Yield, Asset-Backed Financing through Invoice Factoring
Creating Sustainable Value Through Short-Term Receivables Financing
Asset Class
Investment Structure
Risk Management
Liquidity
High-quality receivables from vendors supplying to creditworthy obligors—public listed companies, GLCs, and multinationals. Robust returns with lower risk profiles than traditional unsecured lending.
Capital deployed through structured factoring arrangements where invoices are purchased at a discount and collected at full value upon maturity. This provides the group with legal title to the underlying assets and contractual rights against obligors, creating multiple security layers.
All transactions undergo rigorous vendor and obligor due diligence with legal assignment, corporate guarantees, and controlled accounts. Our risk framework evaluates multiple risk factors, emphasizing obligor payment history and vendor performance. 
With 30-90 day transaction cycles, this strategy enables frequent capital recycling and minimal market correlation. Unlike traditional private equity with 3-5 year lockups, our factoring strategy offers quarterly liquidity windows with short notice periods.
Radstone Capital Group operates within Malaysia’s growing invoice factoring market, often utilising dedicated Special Purpose Vehicles where appropriate to structure transactions and facilitate counterpart relationships. In an environment where traditional bank financing remains constrained by bureaucracy and risk aversion, Radstone provides direct liquidity to businesses—anchored by disciplined underwriting and real-economy exposure.
Factoring remains an underappreciated segment of private credit, particularly in emerging markets. With a proprietary pipeline of high-quality invoices, established compliance frameworks, and strong origination capabilities, Radstone is strategically positioned for scalable and sustainable growth. The Group’s long-standing relationships with leading corporates in Malaysia and across Southeast Asia provide privileged access to premium transaction flow and recurring deal opportunities.
Medical Technology – Investing in Data-Driven Healthcare Transformation
Wearable Diagnostics
Opum's platform integrates advanced sensor technology with real-time patient data to enable accurate monitoring of joint and muscle function—crucial for post-surgery recovery, physiotherapy, and orthopedic assessments.
AI-Driven Treatment Insights
Proprietary machine learning algorithms help clinicians personalise treatment pathways based on objective data, improving outcomes and reducing recovery timelines.
Clinical Utility
The system is already deployed across leading clinics and hospitals, including orthopaedic and rehabilitation centres, with strong adoption by surgeons and therapists seeking evidence-based care models.
Scalable Commercial Model
Cloud-based software-as-a-service (SaaS) offering, enabling scalable deployment across geographies and care settings.
Medicare Capital Group leads the Group's innovation-led healthcare platform, focusing on transformative medical technologies that combine clinical efficacy with commercial scalability. Our core investment is in Opum Technologies, a US based healthtech firm redefining musculoskeletal care through intelligent diagnostics.
By investing in Opum, Medicare Capital Group is championing a new paradigm in healthcare—where data meets design, and patient outcomes drive value creation. We believe the future of medicine is precision-led, non-invasive, and digitally delivered—and Radstone is proud to play a leading role in shaping that future.
Radstone is also a partner with an Australian healthcare provider to drive patients under a unique medical tourism proposition to Malaysia from Australia.
Contact Us
B1011. Block B. Phileo Damansara 2. Jalan Damansara. Petaling Jaya. 46350. Selangor. Malaysia
Tel. +603 7499 5911